血清肿瘤标志物在肺癌辅助诊断中的应用

目的 探讨血清肿瘤标志物在肺癌诊断中的临床价值。方法 收集40例健康人、45例肺部良性疾病患者和90例肺癌患者，采用电化学发光分析检测患者血清中肿瘤标志物细胞角蛋白19（CYFRA21-1）、鳞状细胞癌相关抗原（SCC）和癌胚抗原（CEA），以及胃泌素释放肽前体（pro-GRP）和神经元特异性烯醇化酶（NSE）的含量。结果 健康人组和肺部良性疾病患者组血清NSE、pro-GRP、CYFRA21-1、SCC和CEA水平较肺癌患者组水平低，差异有统计学意义（P<0.01）。NSE和pro-GRP在小细胞肺癌患者中的水平均明显高于其他类型的肺癌患者（P<0.01），CYFRA21-1和SCC在鳞癌患者中的含量比其他类型肺癌患者高（P<0.01）。联合检测此5种血清肿瘤标志物敏感性高于单独的肿瘤标志物（P<0.01）。结论 联合检测NSE、pro-GRP、CYFRA21-1、SCC和CEA可以提高肺癌诊断的灵敏度。

The value of serum tumor markers in the diagnosis of lung cancer

Abstract: Objective To evaluate five serum tumor markers used alone or in combination for the diagnosis of lung cancer. Methods The levels of five serum tumor markers NSE, pro-GRP, CYFRA21-1, SCC and CEA were detected by using Electrochemiluminescence immunoassay among 175 people. Results The levels of the five serum tumor markers of lung cancer patients were significantly higher than those of healthy adults and patients with respiratory infections (P<0.01). The levels of NSE and pro-GRP of patients with small-cell lung cancer were significantly higher than those of patients with other subtypes of lung cancer (P<0.01). The levels of CEA and CYFRA21-1 of patients with squamous-cell carcinoma were significantly higher than those of patients with other subtypes of lung cancer (P<0.01). The sensitivity of the tumor markers in diagnosing lung cancer was significantly enhanced if used in combination (P<0.01). Conclusion These five tumor markers are valuable auxiliary parameters in diagnosing lung cancer.